Once-weekly semaglutide in adults with overweight or obesity

StudyPeer-reviewed research publisher

Source type: Study
Access type: Publisher
Publisher: New England Journal of Medicine
Date: 2021
Added: 2026-06-19

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

Peer-reviewed research publisher

Publisher type: Peer-reviewed journal
Bias profile: Moderate

This source is strongest for clinical outcomes and mechanism and weaker for regulatory status and trial discovery.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->

Regulatory status: 65/100; Context Source
Clinical outcomes: 92/100; Primary Anchor
Mechanism: 90/100; Primary Anchor
Safety: 86/100; Strong Support
Consumer context: 72/100; Context Source
Trial discovery: 65/100; Context Source

Best used for

Primary studies
Systematic reviews
Mechanistic research

Weak for

Regulatory status
Universal consumer recommendations

Used in Viral Vitalism

Primary sourcetimeline1 reference

STEP 1

Roles: Primary source

Show section-level references

Semaglutide obesity trial in adults with overweight or obesity without diabetes.

Primary sourcesignal3 references

GLP-1s Are Not Just a Weight Loss Story

Roles: Primary source

Show section-level references

Primary sourcestudy1 reference

Roles: Primary source

Show section-level references

STEP 1

Claim ledger

Claims supported

Reviewed claim cards that cite this source in the evidence graph.

supported87/100

semaglutide: Semaglutide reduced body weight in adults with obesity or

Semaglutide reduced body weight in adults with obesity or overweight in randomized clinical-trial populations.

Strong human evidence2 sources

supported90/100

glp 1: Semaglutide and tirzepatide should not be collapsed into one

Semaglutide and tirzepatide should not be collapsed into one generic claim because their mechanisms, labels, trial programs, and outcome evidence differ.

Strong human evidence4 sources

supported87/100

glp 1: Semaglutide and tirzepatide produce clinically meaningful average weight loss

Semaglutide and tirzepatide produce clinically meaningful average weight loss in studied adults with obesity or overweight, with results and tolerability varying by drug, dose, and patient context.

Strong human evidence2 sources

partly supported82/100